Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 December 2022 - 8:01AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today reported the
grant of inducement awards to Ricardo Fonseca, its new Vice
President, Operations.
The Compensation Committee of Atara’s Board of Directors granted
Mr. Fonseca 60,000 restricted stock units of Atara’s common stock
and time-based stock options to purchase 69,000 shares of Atara’s
common stock under the Atara Biotherapeutics, Inc. 2018 Inducement
Plan, with a grant date of December 12, 2022, as an inducement
material to the new employee entering into employment with Atara,
in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates. The time-based stock
options vest over four years, with 25 percent vesting on the first
anniversary of the vesting commencement date and the remainder
vesting in 36 equal monthly installments over the following three
years, subject to Mr. Fonseca being continuously employed by Atara
as of such vesting dates. The stock options have a ten-year term
and an exercise price of $4.32 per share, equal to the per share
closing price of Atara’s common stock as reported by Nasdaq on
December 12, 2022.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers, and
autoimmune disease. With our lead program receiving a CHMP positive
opinion for a marketing authorization in Europe, Atara is the most
advanced allogeneic T-cell immunotherapy company and intends to
rapidly deliver off-the-shelf treatments to patients with high
unmet medical need. Our platform leverages the unique biology of
EBV T cells and has the capability to treat a wide range of
EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel® (tabelecleucel) in Phase 3 development
for Epstein-Barr virus-driven post-transplant lymphoproliferative
disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV
antigens as a potential treatment for multiple sclerosis; and
multiple next-generation chimeric antigen receptor T-cell (CAR-T)
immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop
working to bring transformative therapies to those in need. Atara
is headquartered in Southern California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221213006114/en/
INVESTOR & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024